World Journal of
Pharmaceutical and Life Sciences

CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA: A REVIEW

Dr. Vishnu Das*, Dr. Haripriya.H, Dr. Sujala sunil, Dr. Thomas Varghese, Anson Mathew Joseph and Soorya Soman

ABSTRACT

Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a rare disorder of blood coagulation system causing extensive microscopic clot formation in the small blood vessels throughout the body. Caplacizumab, anti- von Willebrand factor Nanobody is the first drug specially approved for its treatment. In this phase 2, controlled study, the patients who were included in the case were given with subcutaneous drug and the control were received only placebo in addition to plasma exchange for 30 days. The primary and the secondary endpoints were analysed by Kaplan– Meier analysis and significance level was done by one-sided log rank test. Complete remission after the initial course of daily plasma exchange was observed more frequently in the Case group than in the control. Caplacizumab, which shows a greater reduction in acute TTP than placebo. It was well tolerable with a manageable risk of increased bleeding and is free of other potential hematologic problems.

[Full Text Article]   [Download Certificate]